Jan 18, 2019
Breast Cancer Patients Take Center Stage in AnaOno at Project Cancerland's 3rd Annual New York Fashion Week Show to Benefit Metavivor
Jan 16, 2019
Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer
Jan 14, 2019
China Cancer Drugs Market 2018-2024: Rising Demand of Targeted Drug Therapy and the Patent Expiration of Key Cancer Drugs
Jan 09, 2019
Positive Assessment Issued for Agendia's MammaPrint®
Jan 08, 2019
Multiple Publications and Presentations Underscore Seno Medical's Value Proposition in Mitigating the Cost and Burden of Unnecessary Breast Biopsies
Jan 02, 2019
Global Mammography System Market: Focus on Products, End Users, 15 Country Analysis, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028
Dec 31, 2018
Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions
Dec 21, 2018
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076
Dec 19, 2018
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
Dec 10, 2018
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
Dec 10, 2018
Beating Cancer Begins with Targeted Therapy
Dec 08, 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 07, 2018
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
Dec 06, 2018
PreludeDx Presents Promising Research in Stage 1 Breast Cancer Patients at the 2018 San Antonio Breast Cancer Symposium
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Dec 06, 2018
Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response
Dec 05, 2018
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 04, 2018
Oncology Consultants Join Agendia's FLEX Big Data Registry Study, Helping to Build a Unique Resource for Breast Cancer Research
Dec 01, 2018
Encore Medical Education Will Publish the Best of SABCS® News From 2018 San Antonio Breast Cancer Symposium (SABCS®)
Nov 29, 2018
New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium